HomeIndustry News › GLP-1

Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S. – Eli Lilly

GLP-1: Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S. – Eli Lilly

Eli Lilly has announced the U.S. availability of Foundayo™ (orforglipron), marking a significant milestone as the first oral GLP-1 receptor agonist approved for weight management. The once-daily pill offers an alternative to injectable GLP-1 medications that have dominated the obesity treatment landscape, potentially expanding access for patients who prefer oral therapy or have difficulty with injections.

Orforglipron works by activating GLP-1 receptors in the body, mimicking the effects of the naturally occurring hormone that regulates appetite and food intake. Unlike injectable GLP-1 medications such as Wegovy and Zepbound, which require weekly subcutaneous injections, Foundayo is taken as a daily pill. This oral formulation required innovative drug delivery technology to overcome the challenge of delivering peptide-based medications through the digestive system, where they would normally be broken down before reaching therapeutic levels.

The approval and launch of Foundayo comes at a time when demand for GLP-1-based weight loss medications has far outpaced supply, leading to widespread shortages and accessibility challenges. An oral option may help ease some of these supply constraints while also appealing to the significant portion of patients who express preference for pills over injections. The medication’s availability could also reduce barriers related to injection site reactions, needle anxiety, and the logistical challenges of storing and administering injectable therapies.

For patients and healthcare providers, Foundayo represents an expansion of treatment options in the rapidly evolving obesity medicine field. The oral formulation may improve adherence for some individuals and could be particularly valuable for those with injection-related concerns. As with other GLP-1 therapies, patients will need to work closely with their healthcare providers to determine if Foundayo is appropriate for their individual circumstances, monitor for potential side effects, and integrate the medication into a comprehensive weight management plan that includes lifestyle modifications.

← Previous Health Canada warns against injecting unauthorized drugs promising anti-aging, weight loss or wellness - CBC Next → Hormone replacement therapy: What doctors want women to know about HRT - ABC7 Los Angeles

Get the Weekly Digest

Research highlights, community picks, and expert insights — every week.

← Back to All News

Popular telehealth providers in this space

Disclosure: The links below are affiliate links — if you click through and make a purchase, GLPbase may earn a small commission at no additional cost to you. This section does not constitute medical advice or a recommendation to seek treatment. Any healthcare decisions are solely between you and your provider. These links do not affect the article above, which is independently researched and written before any affiliate links are added. Our editorial team does not receive commissions, and our analysis is never influenced by affiliate partnerships. For more details, see our Editorial Policy.